
Adult Immunization
Latest News

Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss

Colonoscopy May be the Gold Standard, But Now It's a CRC Screening Bottleneck, Says Mark Fendrick, MD

When Daily Oral PrEP Is Not the Best Fit: Lessons From Clinical Practice

Moderate-to-Severe OSA Tied to Doubled Risk of Brain Microbleeds: Daily Dose

Tezepelumab Achieves Dual Benefit in Adults with Severe Asthma: Daily Dose
Shorts










Latest Videos
Podcasts
Screening
Continuing Medical Education
All News

Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.


Moving patients from considering screening to completing it remains the central challenge in colorectal cancer prevention, Fendrick explained to Patient Care.

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.

The phase 3 REDFINE program showed mean weight loss of 20% at 68 weeks, supporting the dual-mechanism approach that combines semaglutide with cagrilintide.

This is a summary of the multisystem effects of hidradenitis suppurativa followed by practical tips for primary care in recognizing and managing the chronic skin condition.

Your daily dose of the clinical news you may have missed.

The VITESSE trial met its primary endpoint, with the VIASKIN Peanut patch improving desensitization versus placebo in peanut-allergic children aged 4 to 7 years.

Physician researcher Fendrick offers an expert perspective on why removing cost barriers matters, and why navigation and patient realities still determine whether CRC screening succeeds.




























































































































































































































































































